Galapagos NV (AMS:GLPG)
Netherlands · Delayed Price · Currency is EUR | Market Cap | 1.75B |
| Revenue (ttm) | 286.92M |
| Net Income (ttm) | -435.96M |
| Shares Out | 65.90M |
| EPS (ttm) | -6.62 |
| PE Ratio | n/a |
| Forward PE | 8.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 41,991 |
| Average Volume | 80,498 |
| Open | 26.68 |
| Previous Close | 26.54 |
| Day's Range | 26.60 - 27.06 |
| 52-Week Range | 20.00 - 32.74 |
| Beta | -0.05 |
| RSI | 45.58 |
| Earnings Date | Nov 5, 2025 |
About Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ... [Read more]
Financial Performance
In 2024, Galapagos NV's revenue was 275.65 million, an increase of 14.99% compared to the previous year's 239.72 million. Earnings were 74.08 million, a decrease of -65.01%.
Financial StatementsNews
RBC Capital Raises Price Target for GLPG to $32. ...
RBC Capital Raises Price Target for GLPG to $32.00, Maintains Sector Perform Rating | GLPG Stock News
Galapagos NV (GLPG) Q3 2025 Earnings Call Transcript
Galapagos NV (GLPG) Q3 2025 Earnings Call Highlights: Navigating Strategic Shifts Amidst ...
Galapagos NV (GLPG) Q3 2025 Earnings Call Highlights: Navigating Strategic Shifts Amidst Financial Challenges
Q3 2025 Galapagos NV Earnings Call Transcript
Q3 2025 Galapagos NV Earnings Call Transcript
Galapagos NV 2025 Q3 - Results - Earnings Call Presentation
Galapagos to Present New Data from Cell Therapy Program at ASH 2025
Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma
GLPG Crosses Above Average Analyst Target
In recent trading, shares of Galapagos NV (Symbol: GLPG) have crossed above the average analyst 12-month target price of $31.10, changing hands for $31.34/share. When a stock reaches the target an ana...
Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors
Mechelen, Belgium ; October 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG36...
RBC Capital Raises Price Target on Galapagos (GLPG) to $28.00 | GLPG Stock News
RBC Capital Raises Price Target on Galapagos (GLPG) to $28.00 | GLPG Stock News
Galapagos (GLPG) Stock Upgraded by Leerink Partners | GLPG Stock News
Galapagos (GLPG) Stock Upgraded by Leerink Partners | GLPG Stock News
Galapagos (GLPG) Stock Outlook Brightens with Analyst Upgrade
Galapagos (GLPG) Stock Outlook Brightens with Analyst Upgrade
Galapagos (GLPG) to Discontinue Cell Therapy Unit, Shares Fall
Galapagos (GLPG) to Discontinue Cell Therapy Unit, Shares Fall
GILD: Galapagos Plans to Wind Down Cell Therapy Operations
GILD: Galapagos Plans to Wind Down Cell Therapy Operations
Biotech firm Galapagos to wind down cell therapy business
Biotechnology firm Galapagos said on Tuesday it would wind down its cell therapy business after attempts to sell it were unsuccessful, affecting 365 jobs in Europe, China and the U.S.
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company's Ongoing Transformation
Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos Mechelen, Belgium ; Octob...
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company's Ongoing Transformation
Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos
Galapagos Announces Appointment of Fred Blakeslee as General Counsel
Mechelen, Belgium; October 16, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Mr. Fred Blakeslee as Executive Vice President and General Counsel effective O...
Galapagos Receives Non-Binding Offers For Cell Therapy Business
(RTTNews) - Galapagos NV (GLPG) said that it has received a limited number of non-binding offers from consortia—primarily composed of financial investors—expressing interest in acquiring the company's...
Galapagos (GLPG) Explores Strategic Alternatives for Cell Therapy Division
Galapagos (GLPG) Explores Strategic Alternatives for Cell Therapy Division
Galapagos (GLPG) Considers Strategic Options for Cell Therapy Unit
Galapagos (GLPG) Considers Strategic Options for Cell Therapy Unit
Galapagos updates on strategic alternatives for cell therapy business
Galapagos (GLPG) explores strategic options for its Cell Therapy Business, including divestiture, to boost shareholder value.
Biotechnology firm Galapagos receives offers for cell-therapy business
Biotechnology firm Galapagos' board has received non-binding offers from consortia, mainly comprised of financial investors, for its cell-therapy business, the company said on Wednesday.
Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business
Mechelen, Belgium ; October 1, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and its Board of Directors today issued the following statement:
Galapagos Creates New Subscription Right Plan
Mechelen, Belgium; August 7, 2025, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,800,000 subscription rights under a ...
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the United States Food and Drug Administration (FD...